![PDF) Integrating the Results of Phase IV (Postmarketing) Clinical Trial With Four Previous Trials Reinforces the Position that Regranex (Becaplermin) Gel 0.01% Is an EffectiveAdjunct to the Treatment of Diabetic Foot Ulcers PDF) Integrating the Results of Phase IV (Postmarketing) Clinical Trial With Four Previous Trials Reinforces the Position that Regranex (Becaplermin) Gel 0.01% Is an EffectiveAdjunct to the Treatment of Diabetic Foot Ulcers](https://i1.rgstatic.net/publication/237748250_Integrating_the_Results_of_Phase_IV_Postmarketing_Clinical_Trial_With_Four_Previous_Trials_Reinforces_the_Position_that_Regranex_Becaplermin_Gel_001_Is_an_EffectiveAdjunct_to_the_Treatment_of_Diabetic/links/0a85e52e7b8a5d7ec4000000/largepreview.png)
PDF) Integrating the Results of Phase IV (Postmarketing) Clinical Trial With Four Previous Trials Reinforces the Position that Regranex (Becaplermin) Gel 0.01% Is an EffectiveAdjunct to the Treatment of Diabetic Foot Ulcers
![Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF–BB) and becaplermin gel - ScienceDirect Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF–BB) and becaplermin gel - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0002961098001755-gr1.gif)
Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF–BB) and becaplermin gel - ScienceDirect
![Cost-Effectiveness of Becaplermin Gel on Diabetic Foot Ulcer Healing in: Journal of the American Podiatric Medical Association Volume 106 Issue 4 (2016) Cost-Effectiveness of Becaplermin Gel on Diabetic Foot Ulcer Healing in: Journal of the American Podiatric Medical Association Volume 106 Issue 4 (2016)](https://japmaonline.org/view/journals/apms/106/4/i8750-7315-106-4-273-t01.jpeg)
Cost-Effectiveness of Becaplermin Gel on Diabetic Foot Ulcer Healing in: Journal of the American Podiatric Medical Association Volume 106 Issue 4 (2016)
![Efficacy and safety of becaplermin (recombinant human platelet‐derived growth factor‐BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies - Smiell - 1999 - Wound Repair Efficacy and safety of becaplermin (recombinant human platelet‐derived growth factor‐BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies - Smiell - 1999 - Wound Repair](https://onlinelibrary.wiley.com/cms/asset/9e6f9403-c0d9-44fb-ae67-e659f2625ffc/wrr_335_t7.gif)
Efficacy and safety of becaplermin (recombinant human platelet‐derived growth factor‐BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies - Smiell - 1999 - Wound Repair
![These highlights do not include all the information needed to use REGRANEX® gel safely and effectively. See full prescribing information for REGRANEX gel. REGRANEX (becaplermin) gel, for topical useInitial U.S. Approval: 1997 These highlights do not include all the information needed to use REGRANEX® gel safely and effectively. See full prescribing information for REGRANEX gel. REGRANEX (becaplermin) gel, for topical useInitial U.S. Approval: 1997](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=c080f728-figure-01.jpg&id=407088)